Dr. Navid Khan brings more than 20 years of experience across Medical Affairs, R&D, and Commercial functions, with deep expertise in neurology, immunology, and rare diseases. Over his career, he has contributed to more than 40 development programs and seven product launches while building and leading high-performing, multidisciplinary medical organizations.
Prior to joining Vor Bio as Chief Medical Affairs Officer, Dr. Khan served as Head of the Neuromuscular Therapeutic Area in Medical Affairs at argenx, leading four major product launches of efgartigimod (VYVGART & VYVGART HYTRULO) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), and overseeing a fully integrated neuromuscular medical affairs team.
Earlier in his career, Dr. Khan held senior medical affairs and commercial leadership positions at Akouos as VP of Medical Affairs, and at Sarepta Therapeutics as Executive Director of Global Medical Affairs, and Head of HCP Marketing, where he guided strategy, led global medical teams, partnered closely with key opinion leaders, and supported programs from pre-IND through commercialization.
Dr. Khan earned his Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts Lowell and his B.S. in Biochemistry and Molecular Biology from the University of Massachusetts Amherst.